IS7096A - Setin úreataugapeptíð Y Y5 viðtakamótlyf - Google Patents
Setin úreataugapeptíð Y Y5 viðtakamótlyfInfo
- Publication number
- IS7096A IS7096A IS7096A IS7096A IS7096A IS 7096 A IS7096 A IS 7096A IS 7096 A IS7096 A IS 7096A IS 7096 A IS7096 A IS 7096A IS 7096 A IS7096 A IS 7096A
- Authority
- IS
- Iceland
- Prior art keywords
- urothelial
- peptide
- replaced
- receptor antagonists
- antagonists
- Prior art date
Links
- 102100029549 Neuropeptide Y receptor type 5 Human genes 0.000 title 1
- 101710198055 Neuropeptide Y receptor type 5 Proteins 0.000 title 1
- 101710117971 Peptide Y Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30843301P | 2001-07-26 | 2001-07-26 | |
| PCT/US2002/023552 WO2003009845A1 (en) | 2001-07-26 | 2002-07-24 | Substituted urea neuropeptide y y5 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS7096A true IS7096A (is) | 2003-12-31 |
Family
ID=23193972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS7096A IS7096A (is) | 2001-07-26 | 2003-12-31 | Setin úreataugapeptíð Y Y5 viðtakamótlyf |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6667319B2 (is) |
| EP (1) | EP1418913A1 (is) |
| JP (1) | JP2005500338A (is) |
| CN (2) | CN1558764A (is) |
| AR (1) | AR036191A1 (is) |
| AU (1) | AU2002355286B2 (is) |
| CA (1) | CA2454830C (is) |
| HU (1) | HUP0401643A3 (is) |
| IL (1) | IL159643A0 (is) |
| IS (1) | IS7096A (is) |
| MX (1) | MXPA04000707A (is) |
| NZ (1) | NZ530429A (is) |
| PE (1) | PE20030385A1 (is) |
| PL (1) | PL368201A1 (is) |
| TW (1) | TWI300064B (is) |
| WO (1) | WO2003009845A1 (is) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| ES2320979T3 (es) * | 2001-09-24 | 2009-06-01 | Imperial Innovations Limited | Pyy-36 para la reduccion o prevencion de la obesidad. |
| US8058233B2 (en) | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
| US7166575B2 (en) * | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
| GB0300571D0 (en) * | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2004089296A2 (en) | 2003-04-03 | 2004-10-21 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| EP1765311A4 (en) | 2004-03-16 | 2009-04-29 | Univ California | REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| TW200630337A (en) * | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| WO2006045119A2 (en) | 2004-10-20 | 2006-04-27 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| FR2884516B1 (fr) * | 2005-04-15 | 2007-06-22 | Cerep Sa | Antagonistes npy, preparation et utilisations |
| GB0511986D0 (en) * | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| JP2008545010A (ja) * | 2005-06-30 | 2008-12-11 | プロシディオン・リミテッド | Gタンパク質共役受容体アゴニスト |
| FR2894964B1 (fr) * | 2005-12-19 | 2008-02-22 | Cerep Sa | Composes a base de quatre cycles aromatiques, preparation et utilisations |
| AR059826A1 (es) | 2006-03-13 | 2008-04-30 | Univ California | Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble |
| WO2007110449A1 (en) | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
| TW200812963A (en) | 2006-04-13 | 2008-03-16 | Euro Celtique Sa | Benzenesulfonamide compounds and the use thereof |
| WO2007118853A1 (en) | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
| US8088777B2 (en) | 2006-08-30 | 2012-01-03 | Shionogi & Co., Ltd. | Urea derivative |
| TWI428346B (zh) * | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| WO2008124118A1 (en) * | 2007-04-09 | 2008-10-16 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use therof |
| WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| WO2009040659A2 (en) | 2007-09-28 | 2009-04-02 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| ES2627848T3 (es) | 2008-06-04 | 2017-07-31 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| EP2528604B1 (en) | 2010-01-29 | 2017-11-22 | The Regents of the University of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| CA2826649C (en) | 2011-02-25 | 2016-07-26 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| CN102675190A (zh) * | 2012-05-23 | 2012-09-19 | 盛世泰科生物医药技术(苏州)有限公司 | 一种3-(二甲氨基)次甲基-n-甲磺酰基哌啶-4-酮的合成方法 |
| US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| JP2016516004A (ja) | 2013-02-22 | 2016-06-02 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病二環式化合物 |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| EP2968439A2 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| PL3004138T3 (pl) | 2013-06-05 | 2024-07-29 | Bausch Health Ireland Limited | Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| EP3737361A4 (en) | 2018-01-11 | 2021-08-25 | Centaurus Therapeutics | INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR THE TREATMENT OF DISEASES |
| WO2022076365A1 (en) * | 2020-10-06 | 2022-04-14 | Eastman Chemical Company | Aromatic enol ethers |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2928485A1 (de) | 1979-07-14 | 1981-01-29 | Bayer Ag | Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen |
| US4623662A (en) | 1985-05-23 | 1986-11-18 | American Cyanamid Company | Antiatherosclerotic ureas and thioureas |
| US5602024A (en) | 1994-12-02 | 1997-02-11 | Synaptic Pharmaceutical Corporation | DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof |
| ATE232200T1 (de) | 1998-06-08 | 2003-02-15 | Schering Corp | Neuropeptid y5-rezeptorantagonisten |
| EP1129089B1 (en) | 1998-11-10 | 2005-12-28 | Merck & Co., Inc. | Spiro-indolines as y5 receptor antagonists |
| MXPA03002263A (es) * | 2000-09-14 | 2003-06-24 | Schering Corp | Antagonistas de receptor de neuropeptido y y5 de urea sustituidos. |
-
2002
- 2002-07-24 AU AU2002355286A patent/AU2002355286B2/en not_active Ceased
- 2002-07-24 PE PE2002000653A patent/PE20030385A1/es not_active Application Discontinuation
- 2002-07-24 WO PCT/US2002/023552 patent/WO2003009845A1/en not_active Ceased
- 2002-07-24 CA CA002454830A patent/CA2454830C/en not_active Expired - Fee Related
- 2002-07-24 MX MXPA04000707A patent/MXPA04000707A/es active IP Right Grant
- 2002-07-24 CN CNA028189647A patent/CN1558764A/zh active Pending
- 2002-07-24 PL PL02368201A patent/PL368201A1/xx not_active Application Discontinuation
- 2002-07-24 US US10/202,239 patent/US6667319B2/en not_active Expired - Fee Related
- 2002-07-24 JP JP2003515237A patent/JP2005500338A/ja active Pending
- 2002-07-24 TW TW091116480A patent/TWI300064B/zh active
- 2002-07-24 NZ NZ530429A patent/NZ530429A/en unknown
- 2002-07-24 EP EP02752562A patent/EP1418913A1/en not_active Withdrawn
- 2002-07-24 CN CNA2006101215468A patent/CN1911913A/zh active Pending
- 2002-07-24 AR ARP020102785A patent/AR036191A1/es unknown
- 2002-07-24 HU HU0401643A patent/HUP0401643A3/hu unknown
- 2002-07-24 IL IL15964302A patent/IL159643A0/xx unknown
-
2003
- 2003-10-24 US US10/692,559 patent/US7304076B2/en not_active Expired - Fee Related
- 2003-12-31 IS IS7096A patent/IS7096A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2454830A1 (en) | 2003-02-06 |
| NZ530429A (en) | 2005-09-30 |
| HUP0401643A2 (hu) | 2004-12-28 |
| MXPA04000707A (es) | 2004-04-20 |
| EP1418913A1 (en) | 2004-05-19 |
| JP2005500338A (ja) | 2005-01-06 |
| AU2002355286B2 (en) | 2005-10-13 |
| WO2003009845A1 (en) | 2003-02-06 |
| PE20030385A1 (es) | 2003-05-08 |
| CN1558764A (zh) | 2004-12-29 |
| US6667319B2 (en) | 2003-12-23 |
| TWI300064B (en) | 2008-08-21 |
| US20040102474A1 (en) | 2004-05-27 |
| PL368201A1 (en) | 2005-03-21 |
| IL159643A0 (en) | 2004-06-01 |
| AR036191A1 (es) | 2004-08-18 |
| US20030207860A1 (en) | 2003-11-06 |
| US7304076B2 (en) | 2007-12-04 |
| CN1911913A (zh) | 2007-02-14 |
| CA2454830C (en) | 2010-02-02 |
| WO2003009845A9 (en) | 2004-03-11 |
| HUP0401643A3 (en) | 2009-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60136562D1 (de) | Heteroaryl-harnstoff-neuropeptid-y-y5-rezeptor-antagonisten | |
| ATE525378T1 (de) | Himbacinanaloga als thrombinrezeptorantagonisten | |
| ATE368659T1 (de) | Thrombinrezeptorantagonisten | |
| IS7583A (is) | Kalsítóníngen-skyld peptíð viðtaka mótlyf | |
| CY2015029I2 (el) | Τρικυκλικοι ανταγωνιστες υποδοχεα θρομβινης | |
| NO20032612D0 (no) | CXCR3-antagonister | |
| IL159643A0 (en) | Substituted urea neuropeptide y y5 receptor antagonists | |
| IS8482A (is) | Kalsítóníngen-skyldir peptíðviðtaka antagónistar | |
| DE60332816D1 (de) | Nk1-antagonisten | |
| DE60112051D1 (de) | Il-8 rezeptor antagonisten | |
| ATE374183T1 (de) | Nk1-antagonisten | |
| ATE353215T1 (de) | Il-8 rezeptor-antagonisten | |
| ATE370114T1 (de) | Zwitterionische tachykinin-rezeptor-antagonisten | |
| DE60226419D1 (de) | Somatostatin-antagonisten | |
| MA25739A1 (fr) | Antagonistes recepteurs il-8 | |
| NO20024367D0 (no) | IL-8 reseptorantagonister | |
| EE200300335A (et) | Histamiiniretseptori antagonistid | |
| DE60222015D1 (de) | Ccr-3-rezeptorantagonisten vii | |
| DE60134427D1 (de) | Exzitatorische aminosäure-rezeptor-antagonisten | |
| NO20040339L (no) | Nye neuropeptid Y Y5-reseptorantagonister. | |
| NO20024366D0 (no) | IL-8 reseptorantagonister | |
| NO20032973L (no) | Eksitatoriske aminosyrereseptorantagonister | |
| SE0003996D0 (sv) | Receptorantagonister |